| Bioactivity | HVH-2930 is an inhibitor for heat shock protein 90 (HSP90). HVH-2930 inhibits cell viability of BT474 (Trastuzumab (HY-P9907) sensitive) and JIMT-1 (Trastuzumab (HY-P9907) resistant), with IC50 of 6.86 μM and 4.42 μM, through downregulation of HSP90 clients HER2, p-HER2, AKT, p-AKT, cyclin D1 and survivin. HVH-2930 exhibits antitumor efficacy in mouse models. HVH-2930 exhibits good pharmacokinetic characteristics in mice[1]. |
| CAS | 3034605-72-3 |
| Formula | C29H36N4O3 |
| Molar Mass | 488.62 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. La M T, et al. Discovery of Indazole Inhibitors for Heat Shock Protein 90 as Anti-Cancer Agents[J]. European Journal of Medicinal Chemistry, 2024: 116620. |
HVH-2930
CAS: 3034605-72-3 F: C29H36N4O3 W: 488.62
HVH-2930 is an inhibitor for heat shock protein 90 (HSP90). HVH-2930 inhibits cell viability of BT474 (Trastuzumab (HY-P
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.